Search results
Results from the WOW.Com Content Network
4-Fluoromethylphenidate was studied further along with other analogues of (±)-threo-methylphenidate (TMP) to assess their potential as anti-cocaine medications. 4F-MPH was reported as having an ED 50 mg/kg of 0.26 (0.18–0.36), regarding its efficacy as a substitute for cocaine, and a relative potency of 3.33 compared to methylphenidate for ...
4-FMA is considered a Schedule 9 substance in Australia under the Poisons Standard (October 2015). [6] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or ...
An assortment of several designer drugs. Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal.
4-Fluoro-alpha-PHP (4F-PHP) is a recreational designer drug from the substituted cathinone family with stimulant effects, which first appeared on the illicit market in around 2017. [ 2 ] [ 3 ] [ 4 ] See also
4-Fluoroethylphenidate (4F-EPH) is a recreational designer drug from the phenidate family, with stimulant effects. It was first identified in France in March 2016. [ 1 ] It has been used as a nootropic drug, [ 2 ] and was made illegal in the UK in 2017, [ 3 ] and in Sweden in 2018.
4F-MDMB-BINACA (also known as MDMB-4F-BINACA, [2] 4F-MDMB-BUTINACA or 4F-ADB) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. [3] It should not be confused with the amantadine analogue 4F-ABINACA. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018.
threo-4-Methylmethylphenidate (4-MeTMP) is a stimulant drug related to methylphenidate.It is slightly less potent than methylphenidate and has relatively low efficacy at blocking dopamine reuptake despite its high binding affinity, which led to its investigation as a possible substitute drug for treatment of stimulant abuse (cf. nocaine). [1]
α-Pyrrolidinopentiophenone (α-PVP), also known as α-pyrrolidinovalerophenone, O-2387, β-keto-prolintane, prolintanone, [2] [3] or desmethylpyrovalerone, is a synthetic stimulant of the cathinone class developed in the 1960s that has been sold as a designer drug and often consumed for recreational reasons.